Tacrolimus-induced apoptosis and its prevention by interleukins in mitogen-activated human peripheral-blood mononuclear cells

Immunopharmacology. 1998 Mar;39(1):21-30. doi: 10.1016/s0162-3109(97)00094-5.

Abstract

The present study demonstrated that tacrolimus (FK506) induced apoptosis in mitogen-activated human PBMCs and that several interleukins (ILs) prevented the apoptosis. Mitogen-activated PBMCs obtained from healthy subjects treated with 1 ng/ml of FK506 exhibited a DNA-ladder structure in agarose-gel electrophoresis. Moreover, in quantitative analysis of fragmented DNA using cell death detection ELISA, 1 ng/ml of FK506 induced maximal apoptotic induction, whereas > 10 ng/ml of glucocorticoids (GCs) or cyclosporine (CsA) was required to achieve maximal induction of apoptosis in PBMCs. FK506-induced apoptosis was efficiently attenuated by co-addition of ILs including IL-1beta (2 ng/ml), IL-2 (5 ng/ml) and IL-4 (40 ng/ml) into culture. The results showed that FK506 induces apoptosis in mitogen-activated PBMCs at concentrations which exhibited sufficient suppression of PBMC-blastogenesis. The data also suggested that cytokine networks including those via IL-1beta and IL-4 in addition to IL-2 prevent FK506-induced apoptosis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Apoptosis / drug effects*
  • Cells, Cultured
  • DNA Fragmentation / drug effects
  • Humans
  • Immunosuppressive Agents / toxicity*
  • Interleukin-1 / pharmacology*
  • Interleukin-2 / pharmacology*
  • Interleukin-4 / pharmacology*
  • Leukocytes, Mononuclear / drug effects*
  • Leukocytes, Mononuclear / immunology
  • Lymphocyte Activation / drug effects
  • Mitogens
  • Tacrolimus / toxicity*

Substances

  • Immunosuppressive Agents
  • Interleukin-1
  • Interleukin-2
  • Mitogens
  • Interleukin-4
  • Tacrolimus